journal article·2024-07-02

Stepwise Ultra-pH-Sensitive Micelles Overcome a pKa Barrier for Systemic Lymph Node Delivery

Zachary T. Bennett, Gang Huang, Michael T. Dellinger, Baran D. Sumer, Jinming Gao

ACS Nano· Volume 18· Issue 26
Publisher page

Abstract

While local nanoparticle delivery to lymph nodes is well studied, there are few design criteria for intravenous delivery to the entire lymph node repertoire. In this study, we investigated the effect of NP pH transition on lymph node targeting by employing a series of ultra-pH-sensitive (UPS) polymeric micelles. The UPS library responds to pH thresholds (p K a 6.9, 6.2, and 5.3) over a range of physiological pH. We observed a dependence of intravenous lymph node targeting on micelle pH transition. UPS 6.9 (subscript indicates p K a ) shows poor lymph node delivery, while UPS 5.3 delivers efficiently to lymph node sets. We investigated targeting mechanisms of UPS 5.3, observing an accumulation among lymph node lymphatics and a dependence on lymph node-resident macrophages. To overcome the pH-threshold barrier, which limits UPS 6.9, we rationally designed a nanoparticle coassembly of UPS 6.9 with UPS 5.3, called HyUPS. The HyUPS micelle retains the constitutive pH transitions of each polymer, showing stepwise responses to discrete pH thresholds. We demonstrate that HyUPS improves UPS 6.9 delivery to lymph nodes, extending this platform for disease detection of lymph node metastasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced Glycation End Products research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Department of Biomedical Engineering, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Department of Otolaryngology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States

Funding

National Cancer Institute · University of Texas Southwestern Medical Center · Cancer Prevention and Research Institute of Texas

References (62)

Show source-provided references
1. 10.1126/scitranslmed.aal209410.1126/scitranslmed.aal2094 ↗
2. 10.1038/s41565-020-0679-410.1038/s41565-020-0679-4 ↗
3. 10.1126/scitranslmed.aay357510.1126/scitranslmed.aay3575 ↗
4. 10.1002/cncr.2156810.1002/cncr.21568 ↗
5. 10.1152/japplphysiol.00389.200610.1152/japplphysiol.00389.2006 ↗
6. 10.1016/j.addr.2021.11391410.1016/j.addr.2021.113914 ↗
7. 10.1016/j.jconrel.2006.01.00610.1016/j.jconrel.2006.01.006 ↗
8. 10.1038/nbt133210.1038/nbt1332 ↗
9. 10.1021/acs.molpharmaceut.9b0118210.1021/acs.molpharmaceut.9b01182 ↗
10. 10.1016/j.actbio.2022.03.05410.1016/j.actbio.2022.03.054 ↗
11. 10.1016/j.jamcollsurg.2011.11.00610.1016/j.jamcollsurg.2011.11.006 ↗
12. 10.1073/pnas.220784111910.1073/pnas.2207841119 ↗
13. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
14. 10.1038/nri122210.1038/nri1222 ↗
15. 10.1038/s41590-020-00810-310.1038/s41590-020-00810-3 ↗
16. 10.1016/j.cell.2022.10.00610.1016/j.cell.2022.10.006 ↗
17. 10.1038/ncomms219710.1038/ncomms2197 ↗
18. 10.1080/1061186X.2018.143368110.1080/1061186X.2018.1433681 ↗
19. 10.1177/1535370221101076210.1177/15353702211010762 ↗
20. 10.1016/j.celrep.2016.04.00710.1016/j.celrep.2016.04.007 ↗
21. 10.1016/j.nantod.2020.10104510.1016/j.nantod.2020.101045 ↗
22. 10.1038/s41467-020-17291-510.1038/s41467-020-17291-5 ↗
23. 10.1073/pnas.171575611510.1073/pnas.1715756115 ↗
24. 10.1016/j.jconrel.2013.07.00510.1016/j.jconrel.2013.07.005 ↗
25. 10.1021/nn507025910.1021/nn5070259 ↗
26. 10.1038/nature1830010.1038/nature18300 ↗
27. 10.1056/NEJMoa02274910.1056/NEJMoa022749 ↗
28. 10.7150/thno.3026810.7150/thno.30268 ↗
29. 10.1021/nn305466z10.1021/nn305466z ↗
30. 10.1021/ja505315810.1021/ja5053158 ↗
31. 10.7150/thno.4123910.7150/thno.41239 ↗
32. 10.3390/diagnostics1105089110.3390/diagnostics11050891 ↗
33. 10.1182/blood-2013-01-47894110.1182/blood-2013-01-478941 ↗
34. 10.1038/s41577-020-0281-x10.1038/s41577-020-0281-x ↗
35. 10.1038/nature0628710.1038/nature06287 ↗
36. 10.1084/jem.192.10.142510.1084/jem.192.10.1425 ↗
37. 10.1182/blood-2011-07-36740910.1182/blood-2011-07-367409 ↗
38. 10.3389/fimmu.2017.0004510.3389/fimmu.2017.00045 ↗
39. 10.1159/00033700710.1159/000337007 ↗
40. 10.1016/j.jim.2007.08.00410.1016/j.jim.2007.08.004 ↗
41. 10.1021/acsnano.0c0224010.1021/acsnano.0c02240 ↗
42. 10.1101/cshperspect.a02185710.1101/cshperspect.a021857 ↗
43. 10.1182/blood-2010-02-26629610.1182/blood-2010-02-266296 ↗
44. 10.1016/j.celrep.2021.10899310.1016/j.celrep.2021.108993 ↗
45. 10.1002/adma.20160379410.1002/adma.201603794 ↗
46. 10.1016/j.nano.2019.02.00110.1016/j.nano.2019.02.001 ↗
47. 10.1038/ncomms952410.1038/ncomms9524 ↗
48. 10.1038/nrc311010.1038/nrc3110 ↗
49. 10.1002/adfm.20150124810.1002/adfm.201501248 ↗
50. 10.1073/pnas.101838210810.1073/pnas.1018382108 ↗
51. Gress D. M. · 2017 · 8 · 3
53. 10.1093/jnci/djq00810.1093/jnci/djq008 ↗
54. 10.1200/JCO.21.0093410.1200/JCO.21.00934 ↗
55. 10.1001/jama.2013.27780410.1001/jama.2013.277804 ↗
56. 10.1016/j.jamcollsurg.2018.12.00110.1016/j.jamcollsurg.2018.12.001 ↗
57. 10.1001/jama.2013.27893210.1001/jama.2013.278932 ↗
58. 10.1016/S1470-2045(13)70166-910.1016/S1470-2045(13)70166-9 ↗
59. 10.1126/science.aal366210.1126/science.aal3662 ↗
60. 10.1126/science.aal362210.1126/science.aal3622 ↗
61. 10.1038/s41551-016-000610.1038/s41551-016-0006 ↗
62. Huang G. · Nat Biomed Eng · 2020 · 4 · 31410.1038/s41551-019-0416-1 ↗